financetom
Forex World Market Business Cryptocurrency Commodities MAP
financetom
Business
financetom
/
Business
/
NeuroSense Signs Term Sheet for Phase 3 PrimeC Trial in Amyotrophic Lateral Sclerosis
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
NeuroSense Signs Term Sheet for Phase 3 PrimeC Trial in Amyotrophic Lateral Sclerosis
Dec 23, 2024 7:06 AM

09:44 AM EST, 12/23/2024 (MT Newswires) -- NeuroSense Therapeutics ( NRSN ) said Monday it has signed a binding term sheet with an unnamed pharmaceutical company to further develop PrimeC as potential treatment for amyotrophic lateral sclerosis in some key markets.

NeuroSense said it would keep full rights to PrimeC in other key territories.

The term sheet includes a "substantial" upfront payment" and funding for a phase 3 study as well as milestone payments and royalties on annual net sales, NeuroSense said.

A definitive agreement is expected to be finalized in Q1 2025, the company added.

NeuroSense's shares were down more than 16% in early trading Monday.

Price: 1.13, Change: -0.23, Percent Change: -16.91

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Perpetua Resources Insider Sold Shares Worth $402,800, According to a Recent SEC Filing
Perpetua Resources Insider Sold Shares Worth $402,800, According to a Recent SEC Filing
Oct 22, 2024
05:13 PM EDT, 10/22/2024 (MT Newswires) -- Alan Douglas Haslam, Vice President, Permitting, Perpetua Resources Idaho, on October 18, 2024, sold 40,000 shares in Perpetua Resources ( PPTA ) for $402,800. Following the Form 4 filing with the SEC, Haslam has control over a total of 65,571 shares of the company, with 65,571 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1526243/000110465924110608/xslF345X05/tm2426667-1_4seq1.xml Price:...
 --Vicor Q3 Backlog Slumps Almost 14% YoY to $150.6 Million
--Vicor Q3 Backlog Slumps Almost 14% YoY to $150.6 Million
Oct 22, 2024
05:13 PM EDT, 10/22/2024 (MT Newswires) -- Price: 48.05, Change: +4.61, Percent Change: +10.61 ...
 Vicor Q3 Earnings, Revenue Decline; Shares Jump After Hours
Vicor Q3 Earnings, Revenue Decline; Shares Jump After Hours
Oct 22, 2024
05:12 PM EDT, 10/22/2024 (MT Newswires) -- Vicor ( VICR ) reported Q3 earnings late Tuesday of $0.26 per diluted share, down from $0.37 a year earlier. Two analysts polled by Capital IQ expected $0.10. Net revenue for the quarter that ended Sept. 30 was $93.2 million, down from $107.8 million a year earlier. Three analysts surveyed by Capital IQ...
 JBT Q3 Adjusted EPS, Revenue Increase; 2024 Outlook Reiterated -- Shares Jump After Hours
JBT Q3 Adjusted EPS, Revenue Increase; 2024 Outlook Reiterated -- Shares Jump After Hours
Oct 22, 2024
05:12 PM EDT, 10/22/2024 (MT Newswires) -- JBT (JBT) reported Q3 adjusted earnings Tuesday of $1.50 per diluted share, up from $1.11 a year earlier. Four analysts polled by Capital IQ expected $1.41. Revenue for the quarter ended Sept. 30 was $453.8 million, up from $403.6 million a year earlier. Four analysts surveyed by Capital IQ expected $442.2 million. The...
About
Terms and Conditions Privacy policy Cookie Settings Contact Us
Services
Login register
financetom Market Personal Finance Business Economy Cryptocurrency MAP
Links
zpostcode Recruit weather mreligion Yellowpages sport constellation shopping name game directory literature Word tour furnish Lottery tftnews lyrics News digital car dir Edu Finance
Copyright 2023-2026 - www.financetom.com All Rights Reserved